Millennium Management
SGMT icon

Millennium Management’s Sagimet Biosciences SGMT Stock Holding History

Millennium Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-87,800
Closed -$669K – 6420
2025
Q2 		$669K Buy
+87,800
New +$371K ﹤0.01% 4700

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Millennium Management's SGMT Position: Q1 2026 in Review

Millennium Management increased its Sagimet Biosciences (SGMT) stake by 47% in Q1 2026, buying an estimated $1.53M and bringing the position to 862,303 shares worth $4.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3071.

Millennium Management first reported a position in SGMT in Q3 2023 and has held it in 11 quarters since. The position peaked at $5.33M in Q3 2025. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • Millennium Management held 862,303 shares of Sagimet Biosciences worth $4.51M as of Q1 2026.
  • Millennium Management bought 275,356 Sagimet Biosciences shares in Q1 2026, an estimated $1.53M.
  • Sagimet Biosciences made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3071 holding.
  • Millennium Management first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 11 quarters since.
  • Millennium Management's Sagimet Biosciences position peaked at $5.33M in Q3 2025.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.